Your search for apixaban returned 17 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Post remove
Older than 2 years remove
Drugs in the Pipeline remove

Your search for apixaban returned 17 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

Eliquis sNDA Accepted for Review for DVT Prophylaxis

The FDA has accepted Bristol-Myers Squibb's and Pfizer's supplemental New Drug Application for Eliquis (apixaban), an oral direct Factor Xa inhibitor for prophylaxis of deep vein thrombosis (DVT) following hip or knee replacement surgery.
Drugs in the Pipeline

Phase 3 Study of Eliquis for Stroke Prevention

Bristol-Myers Squib and Pfizer announced results from their Phase 3 ARISTOTLE study of Eliquis (apixaban tablet) in patients with atrial fibrillation (AF) and at least one additional risk factor for stroke.
Drugs in the Pipeline

FDA Wants More Data for Anticoagulant Antidote AndexXa

The FDA has issued a Complete Response Letter (CRL) to the Biologics License Application (BLA) of AndexXa (andexanet alfa; Portola) as a reversal agent for life-threatening or uncontrolled bleeding due to Factor Xa inhibitors.
Drugs in the Pipeline

Phase 3 Trial Update of Eliquis for Prevention of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation

Bristol-Myers Squibb and Pfizer announced that the reductions in stroke or systemic embolism, major bleeding and mortality demonstrated with Eliquis (apixaban) compared to warfarin (Coumadin; Bristol-Myers Squibb) in the Phase 3 ARISTOTLE trial were consistent across a wide range of stroke and bleeding risk scores in patients with nonvalvular atrial fibrillation; these were results from a subanalysis from the study.